Compare Enveric Biosciences Inc (ENVB) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Snap On Incorporated — how do they compare? Enveric Biosciences Inc trades at $1.48 (market cap $6.80M), while Snap On Incorporated trades at $360.5 (market cap $18.56B). The key difference: Snap On Incorporated is far larger — about 2729.4× Enveric Biosciences Inc's market cap, and Snap On Incorporated pays a 2.72% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Snap On Incorporated for 36 Days on average.
| ENVB | SNA | |
|---|---|---|
Market Cap | $6.80M | $18.56B |
Volume | 64,867 | 401,326 |
Sector | Health | Industrials |
52-Week High | $10.80 | $419.31 |
52-Week Low | $1.27 | $327.33 |
Typical Hold Time | 14 Days | 36 Days |
Enterprise Value | -$1.49M | $18.20B |
Dividend Yield | — | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
Snap-On Incorporated (SNA) trades at $359.89, down 2.37% on the day, with technical indicators showing bearish momentum despite strong fundamentals. The company maintains robust profitability with 19.6% net margins and 17.58% ROE, supported by consistent earnings beats in recent quarters. Analyst consensus remains bullish with a $449 price target, representing 25% upside potential from current levels.
SNA offers attractive fundamentals with expanding gross margins and solid cash flow generation, though technical weakness and premium valuation present near-term headwinds. The stock's investment case hinges on continued execution of RCI initiatives and diagnostic segment growth, balanced against valuation concerns and mixed technical signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
